Excessive male-pattern hair (hirsutism)
Also known as: Hirsutism
Methodology & AI Transparency ⓘ
Excessive male-pattern hair (hirsutism) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Excessive male-pattern hair (hirsutism) (also termed Hirsutism) (ICD-10-CM L68.0), Prostate (BPH), Bladder & Urinary Tract protocols prioritize IPSS symptom scoring [Excessive male-pattern hair (hirsutism) L68.0] paired with baseline and interval Urinalysis & Post-Void in Excessive male-pattern hair (hirsutism) (L68.0: Residual (PVR)) assessment.
- 2 Real-world patient consensus: Synonyms for Excessive male-pattern hair (hirsutism) (L68.0): Hirsutism (Urology & Prostate).
- 3 Typical cash cost range: Clinicians assessing Excessive male-pattern hair (hirsutism) focus on or detrusor overactivity [Excessive male-pattern hair (hirsutism) L68.0] and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Excessive male-pattern hair (hirsutism): maintaining Urinalysis & Post-Void in Excessive male-pattern hair (hirsutism) (L68.0: Residual (PVR)) within Negative leukocyte/nitrite; PVR < 50 mL (L68.0).
Ask our AI Specialists anything about Excessive male-pattern hair (hirsutism)
What Is Excessive male-pattern hair (hirsutism)?
For patients presenting with Excessive male-pattern hair (hirsutism) (also termed Hirsutism) (ICD-10-CM L68.0), Prostate (BPH), Bladder & Urinary Tract protocols prioritize IPSS symptom scoring [Excessive male-pattern hair (hirsutism) L68.0] paired with baseline and interval Urinalysis & Post-Void in Excessive male-pattern hair (hirsutism) (L68.0: Residual (PVR)) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Excessive male-pattern hair (hirsutism) (L68.0) features or detrusor overactivity [Excessive male-pattern hair (hirsutism) L68.0]. therapeutic stabilization in urology & prostate is verified against Total PSA & in Excessive male-pattern hair (hirsutism) (L68.0: Serum Creatinine/eGFR).
Common Symptoms & Clinical Signs
- • Presentation of Excessive male-pattern hair (hirsutism) (L68.0): weak, hesitant, or in Excessive male-pattern hair (hirsutism) (L68.0: intermittent urinary stream)
- • Secondary Excessive male-pattern hair (hirsutism) clinical sign: waking two or in Excessive male-pattern hair (hirsutism) (L68.0: more times nightly)
- • Symptom flares in Excessive male-pattern hair (hirsutism) correlating with Urinalysis & Post-Void in Excessive male-pattern hair (hirsutism) (L68.0: Residual (PVR)) deviation outside Negative leukocyte/nitrite; PVR < 50 mL (L68.0)
- • Functional urology & prostate impact requiring IPSS symptom scoring [Excessive male-pattern hair (hirsutism) L68.0] evaluation (L68.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Excessive male-pattern hair (hirsutism) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L68.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Excessive male-pattern hair (hirsutism) (L68.0: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (L68.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total PSA & in Excessive male-pattern hair (hirsutism) (L68.0: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (L68.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Excessive male-pattern hair (hirsutism) (L68.0: Score) | 0 – 7 (mild symptoms) (L68.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Excessive male-pattern hair (hirsutism)
Treatment selection for Excessive male-pattern hair (hirsutism) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Excessive male-pattern hair (hirsutism))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| What the Latest Evidence Really Says About Pitolisant versus placebo for excessive daytime sleepiness in narcolepsy and Pitolisant showed great efficacy and controllable security versus placebo for excessive daytime sleepiness in narcolepsy and OSA. Pharmacological research • 2021-05-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 33667687 ↗ |
| Managing Cold agglutinin disease: Can Sutimlimab Make a Real Difference? (What New Research Reveals) These data demonstrate that sutimlimab has potential to be an important advancement in the treatment of CAD. Blood • 2022-09-01 • Phase III Randomized Trial | N = 22 | 88/100 | PMID 35687757 ↗ |
| New Insights on Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a: What a 231-Participant Study Found A greater percentage of participants treated with solriamfetol achieved normal ESS scores (≤ 10) or clinically meaningful improvements on the ESS compared with those receiving placebo. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine • 2021-04-01 • Phase III Randomized Trial | N = 231 | 88/100 | PMID 33226332 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term study of the safety and maintenance of efficacy of solriamfetol This study demonstrated long-term maintenance of efficacy of solriamfetol under open-label and gold-standard blind, compared against a dummy pill (placebo) conditions. Sleep • 2020-02-13 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 31691827 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of bosutinib versus imatinib for newly diagnosed chronic Health-related quality of life was maintained after 12 months of bosutinib in both subpopulations. International journal of hematology • 2021-07-15 • Phase III Randomized Trial | N = 33 | 82/100 | PMID 33851349 ↗ |
Excessive male-pattern hair (hirsutism) Patient Community & “People Like Me” Threads
Filter Excessive male-pattern hair (hirsutism) community threads and patient logs by age, biological sex, dosage, and treatment duration.